MedTrace Logo

Nicotinamide as an Early Alzheimer's Disease Treatment

NCT03061474 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-10-17

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) dementia.

Conditions

Interventions

DRUG

Nicotinamide

Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.

DRUG

Placebo Comparator

Oral Tablet

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Joshua Grill, Ph.D. · Associate Professor of Psychiatry and Human Behavior

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-12
Primary Completion
2022-08-30
Completion
2022-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061474 on ClinicalTrials.gov